

NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

Health Technology Evaluation

Equality impact assessment – Scoping

Ripretinib for treating advanced gastrointestinal stromal tumours after 3 or more treatments (review of TA881) [ID6496]

The impact on equality has been assessed during this evaluation according to the principles of the NICE Equality scheme.

1. Have any potential equality issues been identified during the scoping process (draft scope consultation and scoping workshop discussion), and, if so, what are they?

No potential equality issues were identified during the scoping process.

2. What is the preliminary view as to what extent these potential equality issues need addressing by the Committee?

No potential equality issues were highlighted that will need to be addressed by the committee.

3. Has any change to the draft scope been agreed to highlight potential equality issues?

No changes have been made to the draft scope in response to potential equality issues.

4. Have any additional stakeholders related to potential equality issues been identified during the scoping process, and, if so, have changes to the stakeholder list been made?

No stakeholders related to potential equality issues been identified during the scoping process.

Approved by Associate Director (name): Ian Watson

Date: 10 March 2025

Health Technology Evaluation: Scoping

Equality impact assessment for the Health Technology Evaluation of Ripretinib for treating advanced gastrointestinal stromal tumours after 3 or more treatments (review of TA881)

[ID6496]

Issue date: March 2025

2 of 2